Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIRIUS-SLE extension study of ianalumab long-term safety in systemic lupus erythematosus
CTR20241291Phase 3Active
- Sponsor
- Novartis
- Start
- Aug 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of ianalumab in systemic lupus erythematosus (SLE), sponsored by Novartis. Started Aug 2024; status: active.
02
Drugs
ianalumab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on CTR20241291.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241291.